282 related articles for article (PubMed ID: 33091154)
1. Vaccine design based on 16 epitopes of SARS-CoV-2 spike protein.
He J; Huang F; Zhang J; Chen Q; Zheng Z; Zhou Q; Chen D; Li J; Chen J
J Med Virol; 2021 Apr; 93(4):2115-2131. PubMed ID: 33091154
[TBL] [Abstract][Full Text] [Related]
2. Exploring the out of sight antigens of SARS-CoV-2 to design a candidate multi-epitope vaccine by utilizing immunoinformatics approaches.
Safavi A; Kefayat A; Mahdevar E; Abiri A; Ghahremani F
Vaccine; 2020 Nov; 38(48):7612-7628. PubMed ID: 33082015
[TBL] [Abstract][Full Text] [Related]
3. An in silico deep learning approach to multi-epitope vaccine design: a SARS-CoV-2 case study.
Yang Z; Bogdan P; Nazarian S
Sci Rep; 2021 Feb; 11(1):3238. PubMed ID: 33547334
[TBL] [Abstract][Full Text] [Related]
4. A Bioinformatics Approach for the Prediction of Immunogenic Properties and Structure of the SARS-COV-2 B.1.617.1 Variant Spike Protein.
Srivastava VK; Kaushik S; Bhargava G; Jain A; Saxena J; Jyoti A
Biomed Res Int; 2021; 2021():7251119. PubMed ID: 34651048
[TBL] [Abstract][Full Text] [Related]
5. Immunoinformatics-guided design of an epitope-based vaccine against severe acute respiratory syndrome coronavirus 2 spike glycoprotein.
Rakib A; Sami SA; Mimi NJ; Chowdhury MM; Eva TA; Nainu F; Paul A; Shahriar A; Tareq AM; Emon NU; Chakraborty S; Shil S; Mily SJ; Ben Hadda T; Almalki FA; Emran TB
Comput Biol Med; 2020 Sep; 124():103967. PubMed ID: 32828069
[TBL] [Abstract][Full Text] [Related]
6. Identification of HLA-A*24:02-Restricted CTL Candidate Epitopes Derived from the Nonstructural Polyprotein 1a of SARS-CoV-2 and Analysis of Their Conservation Using the Mutation Database of SARS-CoV-2 Variants.
Takagi A; Matsui M
Microbiol Spectr; 2021 Dec; 9(3):e0165921. PubMed ID: 34937174
[TBL] [Abstract][Full Text] [Related]
7. Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies.
Ahmed SF; Quadeer AA; McKay MR
Viruses; 2020 Feb; 12(3):. PubMed ID: 32106567
[TBL] [Abstract][Full Text] [Related]
8. Prediction and evolution of B cell epitopes of surface protein in SARS-CoV-2.
Lon JR; Bai Y; Zhong B; Cai F; Du H
Virol J; 2020 Oct; 17(1):165. PubMed ID: 33121513
[TBL] [Abstract][Full Text] [Related]
9. Potential Cross-Reactive Immunity to SARS-CoV-2 From Common Human Pathogens and Vaccines.
Reche PA
Front Immunol; 2020; 11():586984. PubMed ID: 33178220
[TBL] [Abstract][Full Text] [Related]
10. Immunoinformatics design of a structural proteins driven multi-epitope candidate vaccine against different SARS-CoV-2 variants based on fynomer.
Sarvmeili J; Baghban Kohnehrouz B; Gholizadeh A; Shanehbandi D; Ofoghi H
Sci Rep; 2024 May; 14(1):10297. PubMed ID: 38704475
[TBL] [Abstract][Full Text] [Related]
11. Immunoinformatics design of B and T-cell epitope-based SARS-CoV-2 peptide vaccination.
Khan MS; Khan IM; Ahmad SU; Rahman I; Khan MZ; Khan MSZ; Abbas Z; Noreen S; Liu Y
Front Immunol; 2022; 13():1001430. PubMed ID: 36685569
[TBL] [Abstract][Full Text] [Related]
12. Common low complexity regions for SARS-CoV-2 and human proteomes as potential multidirectional risk factor in vaccine development.
Gruca A; Ziemska-Legiecka J; Jarnot P; Sarnowska E; Sarnowski TJ; Grynberg M
BMC Bioinformatics; 2021 Apr; 22(1):182. PubMed ID: 33832440
[TBL] [Abstract][Full Text] [Related]
13. PeptiVAX: A new adaptable peptides-delivery platform for development of CTL-based, SARS-CoV-2 vaccines.
Feola S; Chiaro J; Fusciello M; Russo S; Kleino I; Ylösmäki L; Kekäläinen E; Hästbacka J; Pekkarinen PT; Ylösmäki E; Capone S; Folgori A; Raggioli A; Boni C; Tiezzi C; Vecchi A; Gelzo M; Kared H; Nardin A; Fehlings M; Barban V; Ahokas P; Viitala T; Castaldo G; Pastore L; Porter P; Pesonen S; Cerullo V
Int J Biol Macromol; 2024 Mar; 262(Pt 1):129926. PubMed ID: 38331062
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and immunological evaluation of synthetic peptide based anti-SARS-CoV-2 vaccine candidates.
Zhao Q; Gao Y; Xiao M; Huang X; Wu X
Chem Commun (Camb); 2021 Feb; 57(12):1474-1477. PubMed ID: 33443248
[TBL] [Abstract][Full Text] [Related]
15. A multifaceted approach for identification, validation, and immunogenicity of naturally processed and in silico-predicted highly conserved SARS-CoV-2 peptides.
Ratishvili T; Quach HQ; Haralambieva IH; Suryawanshi YR; Ovsyannikova IG; Kennedy RB; Poland GA
Vaccine; 2024 Jan; 42(2):162-174. PubMed ID: 38105139
[TBL] [Abstract][Full Text] [Related]
16. Immune Epitopes of SARS-CoV-2 Spike Protein and Considerations for Universal Vaccine Development.
Magazine N; Zhang T; Bungwon AD; McGee MC; Wu Y; Veggiani G; Huang W
Immunohorizons; 2024 Mar; 8(3):214-226. PubMed ID: 38427047
[TBL] [Abstract][Full Text] [Related]
17. Enhancing explainable SARS-CoV-2 vaccine development leveraging bee colony optimised Bi-LSTM, Bi-GRU models and bioinformatic analysis.
Ozsahin DU; Ameen ZS; Hassan AS; Mubarak AS
Sci Rep; 2024 Mar; 14(1):6737. PubMed ID: 38509174
[TBL] [Abstract][Full Text] [Related]
18. Leveraging the immunoinformatics approach for designing the SARS-CoV-2 omicron-specific antigenic cassette of mRNA vaccine.
Wadapurkar R; Singh S; Singh A
Vaccine; 2024 Mar; 42(7):1630-1647. PubMed ID: 38336561
[TBL] [Abstract][Full Text] [Related]
19. SARS-CoV-2 Proteome Harbors Peptides Which Are Able to Trigger Autoimmunity Responses: Implications for Infection, Vaccination, and Population Coverage.
Karami Fath M; Jahangiri A; Ganji M; Sefid F; Payandeh Z; Hashemi ZS; Pourzardosht N; Hessami A; Mard-Soltani M; Zakeri A; Rahbar MR; Khalili S
Front Immunol; 2021; 12():705772. PubMed ID: 34447375
[TBL] [Abstract][Full Text] [Related]
20. Immunogenic amino acid motifs and linear epitopes of COVID-19 mRNA vaccines.
Wisnewski AV; Redlich CA; Liu J; Kamath K; Abad QA; Smith RF; Fazen L; Santiago R; Campillo Luna J; Martinez B; Baum-Jones E; Waitz R; Haynes WA; Shon JC
PLoS One; 2021; 16(9):e0252849. PubMed ID: 34499652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
